Multiple Sclerosis – LEMTRADA® PASS

Multiple Sclerosis – LEMTRADA® PASS

About this clinical trial

LEMTRADA is an observational study (no experimental intervention used) to monitor the long term outcomes of multiple sclerosis patients following their treatment with LEMTRADA® (alemtuzumab)

It is hoped that the study improves the understanding of the benefits and/or potential side effects after treatment with this drug.

Patients Required

Estimated completion

Follow-up completed 2030

Total participants required

Closed to recruitment

Study location

The Wesley Hospital

Trial title

A prospective, multicenter, observational, post-authorisation safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis


Eligibility criteria:

  • Diagnosis of relapsing multiple sclerosis
  • Treated with LEMTRADA® PASS within 8 weeks of study entry

Additional information

You can find out more about this clinical trial by completing the below contact form.

Lead investigator

Professor Pamela McCombe

If you would like more information about this clinical trial, please complete the Multiple Sclerosis LEMTRADA PASS contact form


Wesley Medical Research

Scroll to Top